Completed OBSERVATIONAL NCT01582217

Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition (TRIAGE)

TRIAGE: Patients Undergoing Percutaneous Coronary Interventions to Improve Clinical Outcomes Through Optimal Platelet Inhibition

Sponsor: Accumetrics, Inc.

Conditions Aspirin Clopidogrel Dual Antiplatelet Therapy Percutaneous Coronary Intervention

Updated 8 times since 2017 Last updated: Dec 22, 2015 Started: Mar 31, 2012 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01582217, this observational or N/A phase trial focuses on Aspirin and Clopidogrel and remains completed. Sponsored by Accumetrics, Inc., it has been updated 8 times since 2012, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Mar 2024 — Jul 2024 [monthly]

Completed
Jan 2021 — Mar 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Sep 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Sep 2017 [monthly]

Completed NA

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Accumetrics, Inc.
Daiichi Sankyo
Icahn School of Medicine at Mount Sinai

Data source: Icahn School of Medicine at Mount Sinai

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States